

SC/K/A/cmb/(dc)
July 8, 2004

JUL 15 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Keizo Koya, LiJun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu,
Mitsunori Ono, and Zhi-Qiang Xia

Application No.: 10/803,798

Group Art Unit: 1614

Filed: March 18, 2004

Examiner: Not assigned

Confirmation No.: 5620

Title: TAXOL ENHANCER COMPOUNDS

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
7/13/2004	<i>[Signature]</i>
Date	Signature
Meredith Murray	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☒ Copies of the cited references (AN, AO, AX and AY) are enclosed.
 - ☒ Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
 - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
 - ☒ The listed references (AN, AO, AX and AY) were cited in the enclosed International Search Report in a counterpart foreign application.
 - ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

☒ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 10/846,152, by Keizo Koya, Lijun Sun, Shoujun Chen,
Noriaki Tatsuta, Yaming Wu and Mitsunori Ono, filed May 14, 2004,
Docket No.: 3211.1000-045

U.S. Patent Application No. 10/758,589, by Keizo Koya, Lijun Sun, Yaming Wu,
Timothy Korb, Dan Zhou, Zhenjian Du, Shoujun Chen, Noriaki Tatsuta, Guiqing
Liang, and Mitsunori Ono, filed, January 15, 2004, Docket No.: 3211.1001-001

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

☒ A copy of each above-cited application, including the current claims, is enclosed.

☐ A copy of each above-cited application, including the current claims, is enclosed, except
those entered in prior application, U.S. Application No. [], to which priority under
35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which
references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the
accompanying Reply. A copy of this Statement is enclosed.


☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is
enclosed.

☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By



Craig K. Anderson
Registration No.: 54,961
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133


Dated: 

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3211.1000-044APPLICATION NO.
10/803,798SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION

July 8, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR
Keizo KoyaFILING DATE
March 18, 2003EXAMINER
Not assignedCONFIRMATION NO.
5620GROUP
1614

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AH	4,012,360	03-15-1977	Schwarzenbach et al.
	AI	6,435,787 B1	08-20-2002	John
	AJ	6,455,515 B2	09-24-2002	Gypser et al.
	AK	6,703,426 B1	03-09-2004	Miles et al.
	AA2	20030195258 A1	10-16-2003	Koya et al.
	AB2	20030119914 A1	06-26-2003	Koya et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	AN	WO 03/006428 A	01-23-2003	SBR Pharmaceuticals Corp.		
	AO	WO 03/006430 A	01-23-2003	SBR Pharmaceuticals Corp.		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AX	Barry, V. C. , <i>et al.</i> , "Anticancer Agents-III. Synthesis and Anticancer Activity of Some Bis-Thiosemicarbazones and Thiosemicarbazides," <i>Proc. R.I.A.</i> 65:309-324 1967).
	AY	O'Callaghan, C. N., "Anticancer Agents-X. Cyclisation of 1-Acyl-4-Alkylthiosemicarbazide Derivatives to 1,2,4-Triazoline-3-Thiones in the Presence of Hydrazine," <i>Proc. R.I.A.</i> 74:455-461 (1974).

EXAMINER

DATE CONSIDERED